We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...

Want to stay on top of the science and politics driving biotech ... a shortage of the primary alternative for children. Eli Lilly CEO Dave Ricks made $114 million last year, according to a new ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says Trump Should Carry A Howitzer And Be Soft.

The University of Copenhagen is excited to announce Maxwell Biosciences as Tier 1 Sponsor of the 12th Aging Research & Drug ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly has recently attracted significant attention from investors, but its stock performance remains a mixed bag. The company's stock has underperformed the broader market, with a -3.7% return in ...

AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli Lilly ...